Combating Illicit Xylazine Act
Introduced Feb 12, 2025 by Rep. Jimmy Panetta
The House passed it. The Senate has to pass it before it can reach the President.
This bill regulates xylazine under the Controlled Substances Act (CSA).
Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.
This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.
Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.
Read the full summary on Congress.govSummary by the Congressional Research Service.
No recorded roll-call vote on this bill — it may have passed by voice vote or unanimous consent, which don't record individual votes.
- Sep 16, 2026Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
- Sep 15, 2026Motion to reconsider laid on the table Agreed to without objection.
- Sep 15, 2026On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5671-5672)
- Sep 15, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Sep 15, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 1266.
- Sep 15, 2026Considered under suspension of the rules. (consideration: CR H5671-5673)
- Sep 15, 2026Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- Sep 14, 2026Placed on the Union Calendar, Calendar No. 715.
- Sep 14, 2026Committee on the Judiciary discharged.
- Sep 14, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-816, Part I.
- Jul 21, 2026Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0.
- Jul 21, 2026Committee Consideration and Mark-up Session Held
- Jul 20, 2026Committee Consideration and Mark-up Session Held
- Jun 25, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
- Jun 25, 2026Subcommittee Consideration and Mark-up Session Held
- Feb 12, 2025Referred to the Subcommittee on Health.
- Feb 12, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Feb 12, 2025Introduced in House